CLINICAL TRIALS PROFILE FOR ENDARI
✉ Email this page to a colleague
All Clinical Trials for ENDARI
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03947879 ↗ | The Effect of Pharmaceutical Grade L-glutamine (Endari) on Glycemic Control in Patients With Diabetes Mellitus Type II | Not yet recruiting | Hawaii Pacific Health | Phase 1 | 2019-05-01 | The study is an initial non-blinded, non-placebo controlled trial to determine the efficacy of L-glutamine in lowering blood sugar in patients with diabetes mellitus type II without sickle cell anemia. |
| NCT04634539 ↗ | Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer | Recruiting | Emmaus Medical, Inc. | Phase 1 | 2021-05-13 | This study will enroll a total of 16 patients with advanced pancreatic cancer at Cedars-Sinai Medical Center. All subjects will receive combination therapy of gemcitabine, nab-paclitaxel, and L-glutamine. The study investigates what the appropriate dosage of L-glutamine is so that there is the lowest risk of side effects, and whether the supplement will make standard chemotherapy of gemcitabine and nab-paclitaxel more effective in treating advanced pancreatic cancer. |
| NCT04634539 ↗ | Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer | Recruiting | Jun Gong, MD | Phase 1 | 2021-05-13 | This study will enroll a total of 16 patients with advanced pancreatic cancer at Cedars-Sinai Medical Center. All subjects will receive combination therapy of gemcitabine, nab-paclitaxel, and L-glutamine. The study investigates what the appropriate dosage of L-glutamine is so that there is the lowest risk of side effects, and whether the supplement will make standard chemotherapy of gemcitabine and nab-paclitaxel more effective in treating advanced pancreatic cancer. |
| NCT04684381 ↗ | Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients | Recruiting | Emmaus Medical, Inc. | Phase 4 | 2021-01-04 | L-glutamine has been approved in the US to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients 5 years of age and older. The purpose of this single-center, open-label, phase 4 study is to evaluate the pharmacokinetic characteristics and safety of L-glutamine in patients with SCD. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ENDARI
Condition Name
Clinical Trial Locations for ENDARI
Trials by Country
Clinical Trial Progress for ENDARI
Clinical Trial Phase
Clinical Trial Sponsors for ENDARI
Sponsor Name
